Krystal Biotech announced that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis or CF. KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered via a nebulizer. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation. "We are pleased that the European Commission has granted orphan drug designation to KB407, which we believe is an important step toward advancing this option to treat patients with CF," said Suma Krishnan, President of Research and Development at Krystal Biotech.The U.S. Food and Drug Administration has also granted Orphan Drug designation for KB407 to treat patients with CF.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
- Krystal Biotech PDUFA delay ‘a minor setback,’ says Chardan
- H.C. Wainwright sees no further delay after Krystal’s B-VEC PDUFA date revision
- Krystal Biotech announces FDA 3-month extension of BLA PDUFA date
- New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
